Related Experiment Videos
CI-973, a new platinum derivative with potential antileukemic activity
S O'Brien1, H Kantarjian, E Freireich
1Department of Hematology, University of Texas M. D. Anderson Cancer Center, Houston 77030.
Cancer Research
|August 1, 1992
Summary
CI-973 effectively inhibited various leukemia and Chinese hamster ovary cell lines, including drug-resistant types. Some resistant cell lines showed collateral sensitivity to CI-973, indicating potential therapeutic value in leukemia treatment.
Area of Science:
- Pharmacology
- Cancer Biology
- Drug Discovery
Background:
- Drug resistance in leukemia poses a significant clinical challenge.
- Novel therapeutic agents are needed to overcome resistance mechanisms.
- CI-973 is an investigational compound with potential anti-cancer activity.
Purpose of the Study:
- To evaluate the efficacy of CI-973 against human leukemia cell lines and their drug-resistant counterparts.
- To assess the potential for collateral sensitivity in drug-resistant leukemia cells.
- To determine the dose- and time-dependency of CI-973's cytotoxic effects.
Main Methods:
- Utilized a panel of human leukemia cell lines (HL-60, KBM3) and a Chinese hamster ovary (CHO) line, along with their drug-resistant variants (resistant to doxorubicin, amsacrine, or cytarabine).
- Assessed CI-973's effects using growth inhibition assays and colony formation inhibition assays.
- Compared the cytotoxic effects of short (1-hour) versus prolonged (4-day) exposure to CI-973.
Main Results:
- CI-973 demonstrated inhibitory effects across all tested cell lines, including drug-resistant ones.
- Collateral sensitivity to CI-973 was observed in two out of three amsacrine-resistant lines and the single cytarabine-resistant line.
- Prolonged exposure (4 days) to CI-973 resulted in significantly greater cell kill compared to short exposure (1 hour).
- Clonogenic assays indicated exponential cell killing over a 3-log unit range.
- The concentrations of CI-973 required for 50% cell kill were substantially lower than peak plasma levels observed in a Phase I solid tumor study.
Conclusions:
- CI-973 exhibits potent cytotoxic activity against a range of leukemia cell lines, including those with acquired resistance.
- The observed collateral sensitivity suggests a potential role for CI-973 in treating resistant leukemia.
- The drug's efficacy is enhanced by prolonged exposure, supporting further investigation in clinical settings.
- Phase I clinical trials of CI-973 via continuous infusion in acute leukemia are underway.